Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Cancer Medicine|July 13, 2021
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223Esmail M Al-Ezzi, Husam A Alqaisi, Marco A J Iafolla, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2018
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II ConsortiumStephanie Lheureux, Anna Tinker, Blaise Clarke, et al.
Nature Communications|September 18, 2022
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancerRadia M Johnson, Xueping Qu, Chu-Fang Lin, et al.
Journal of Gastrointestinal Oncology|January 13, 2023
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinomaKyaw L Aung, Elaine McWhirter, Stephen Welch, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancerVladimir Roudko, Diane Marie Del Valle, Emir Radkevich, et al.
Leukemia & Lymphoma|February 17, 2015
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemiaJonathan How, Mark D Minden, Leber Brian, et al.
Nature Genetics|June 11, 2026
Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy responseAmanda R Moore, Brian Biehs, Noelyn Kljavin, et al.
Pageof 17